Recruiting

Cancer Genetic Testing in Ethnic Populations

This clinical trial examines the integration of cancer genetic testing in various ethnic populations. Studying individuals and families at risk of cancer may help identify cancer genes and other persons at risk. The information from this study may provide an opportunity for cancer risk stratification and individualized screening in these ethnic populations.

ClinicalTrials.gov IDNCT04475640

PhaseNA

Enrollment1800

SponsorMayo Clinic

Age18 Years

SexALL

I'm interested View official listing

Conditions studied

Breast Carcinoma, Carcinoma of Unknown Primary, Central Nervous System Carcinoma, Digestive System Carcinoma, Genitourinary System Carcinoma, Head and Neck Carcinoma, Malignant Brain Neoplasm, Malignant Female Reproductive System Neoplasm, Malignant Musculoskeletal Neoplasm, Malignant Solid Neoplasm, Skin Carcinoma

About this study

Interventions

Procedure: Biospecimen Collection — Undergo collection of blood sample
Other: Genetic Testing — Undergo genetic testing

Primary outcomes

Prevalence of pathogenic germline mutations in enrolled patients within each cancer site (Study completion (2 years))
Prevalence of positive pathogenic germline mutations (Study completion (2 years))
Rate of mutation detection via genetic testing to clinical practice guidelines of traditional family history criteria (Study completion (2 years))
Impact of germline genetic testing on both therapeutic management and targeted cancer prevention (Study completion (2 years))

Eligibility information

Inclusion Criteria: * Patients at least 18 years of age * Individuals diagnosed with any solid tumor cancer including, but not limited to, gastrointestinal, breast, gynecological, genitourinary, skin, central nervous system (CNS)/brain, head/neck, musculoskeletal or cancer of unknown primary; and presenting to Mayo Clinic (MC Arizona or MC Florida) for clinical management/treatment; and patients receive genetic testing as described above * Self-identified as being from various ethnic populations including Hispanic/Latino, Native American/Alaskan, African American (including of African descent), Asian and other European populations * Blood collection is feasible (health, access and/or tolerability) for requested blood sample(s) * Individuals have agreed to participate and signed the study informed consent form Exclusion Criteria: * Patients who have had prior germline genetic testing involving a 40+ gene panel within the last 24 months at Mayo Clinic and available for review by the research coordinator at time of consent * Past or current history of hematological cancer (including leukemias, multiple myeloma) * All bone marrow transplants

Study locations

Mayo Clinic in Arizona, Scottsdale, Arizona 85259 United States
Mayo Clinic in Florida, Jacksonville, Florida 32224-9980 United States

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.